GO:0018230 peptidyl-L-cysteine S-palmitoylation: Protein Lipidation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018230 peptidyl-L-cysteine S-palmitoylation is the covalent attachment of a palmitoyl group to a cysteine sulfur atom, forming peptidyl-S-palmitoyl-L-cysteine.
• It is a reversible lipid modification that controls protein membrane targeting, trafficking, stability and protein-protein interactions.
• The reaction is written by ZDHHC-family palmitoyl acyltransferases and erased by acyl-protein thioesterases such as APT1/APT2.
• S-palmitoylation regulates major disease-relevant proteins including GPX4, gasdermin D, FASN, YTHDF3 and ATG16L1.
• Dysregulated palmitoylation is implicated in cancer, ferroptosis, inflammatory cell death and autophagy-related pathology.
• CRISPR knockout, point-mutation, knock-in and overexpression models are key tools for causal dissection of palmitoylation enzymes and substrates.
Description
GO:0018230 peptidyl-L-cysteine S-palmitoylation is the biological process in which a palmitoyl group is covalently attached to the sulfur atom of a cysteine residue within a protein, generating peptidyl-S-palmitoyl-L-cysteine. This enzyme-catalyzed, reversible lipid modification is a central form of protein S-acylation and a major mechanism for directing soluble proteins to membrane compartments. Because the thioester bond linking palmitate to cysteine is labile, S-palmitoylation operates as a dynamic switch rather than a permanent anchor, allowing cycles of membrane association and release. Researchers study this process because it influences protein localization, stability, trafficking and interaction networks across nearly every cell type. The modification is written by DHHC-motif palmitoyl acyltransferases and removed by thioesterases, creating an enzymatically controlled cycle. Beyond housekeeping roles, S-palmitoylation has emerged as a regulatory node in cancer, cell death and autophagy pathways. For example, palmitoylation-dependent regulation of GPX4 suppresses ferroptosis, linking this modification directly to oxidative cell death. Similarly, ROS-dependent S-palmitoylation activates gasdermin D, connecting the process to inflammatory signaling. In cancer, ZDHHC20-mediated S-palmitoylation of FASN promotes hepatocarcinogenesis, while ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA and promotes pancreatic cancer progression. These findings illustrate why GO:0018230 is now a high-priority area for mechanistic and therapeutic research.
peptidyl-L-cysteine S-palmitoylation At A Glance
| GO ID | GO:0018230 |
|---|---|
| GO term | peptidyl-L-cysteine S-palmitoylation |
| Ontology | biological_process |
| Synonym | peptidyl-cysteine S-palmitoylation; peptidyl-S-palmitoyl-L-cysteine biosynthetic process from peptidyl-cysteine |
| Major function | Covalent attachment of palmitate to cysteine sulfur, controlling protein membrane association and trafficking |
| Enzyme writers | ZDHHC-family palmitoyl acyltransferases |
| Enzyme erasers | Acyl-protein thioesterases such as APT1 and APT2 |
| Reversibility | Thioester bond is labile and dynamically cycles |
| Disease relevance | Cancer, ferroptosis, inflammatory cell death and autophagy-related pathology |
What Is GO:0018230?
In plain terms, peptidyl-L-cysteine S-palmitoylation is the process of attaching a fatty acid called palmitate to a specific sulfur atom on a cysteine residue of a protein. The QuickGO definition states that this is the covalent attachment of a palmitoyl group to a sulfur (S) atom within a cysteine residue to form peptidyl-S-palmitoyl-L-cysteine. The reaction creates a thioester bond between the palmitoyl group and the cysteine sulfur, and this bond can be hydrolyzed to reverse the modification. The process is therefore distinct from N-terminal or other lipid modifications because it targets cysteine sulfur specifically. It is also known by synonyms such as peptidyl-cysteine S-palmitoylation and peptidyl-S-palmitoyl-L-cysteine formation from peptidyl-cysteine.
Why Is peptidyl-L-cysteine S-palmitoylation Important in Cell Biology?
Peptidyl-L-cysteine S-palmitoylation matters because it is a reversible, enzymatically controlled modification that determines where a protein sits in the cell and how long it survives, making it a central regulator of signaling, trafficking and cell fate. Because the modification is dynamic, it allows cells to rapidly remodel protein localization in response to stimuli, and its dysregulation has been linked to cancer, cell death and autophagy pathways. The clinical relevance is underscored by findings that palmitoylation controls GPX4-dependent ferroptosis, gasdermin D activation, FASN-driven hepatocarcinogenesis and YTHDF3-mediated MYC mRNA stabilization in pancreatic cancer.
• Controls reversible membrane targeting and trafficking of soluble and transmembrane proteins.
• Regulates protein stability and protein-protein interactions.
• Modulates ferroptosis through palmitoylation-dependent regulation of GPX4.
• Activates gasdermin D in a ROS-dependent manner, linking palmitoylation to inflammatory cell death.
• Promotes hepatocarcinogenesis via ZDHHC20-mediated S-palmitoylation of FASN.
• Stabilizes MYC mRNA through ZDHHC20-mediated S-palmitoylation of YTHDF3 in pancreatic cancer.
• Facilitates LC3 lipidation and autophagosome formation via ZDHHC7-mediated S-palmitoylation of ATG16L1.
• Represents a therapeutic target space in oncology and cell-death-related disease.
• Provides a mechanistic explanation for how metabolic and signaling cues converge on protein localization.
• Enables CRISPR-based causal testing of writer, eraser and substrate genes.
What Happens During peptidyl-L-cysteine S-palmitoylation?
Substrate recognition and cysteine selection
In simple terms: The enzyme first finds the right protein and the right cysteine residue to modify.
S-palmitoylation begins with recognition of a substrate protein by a palmitoyl acyltransferase, typically a ZDHHC-family enzyme, which selects specific cysteine residues for modification. Substrate selection is not random; it depends on sequence context, membrane proximity and accessory protein interactions that position the target cysteine near the catalytic site. Because many substrates contain multiple cysteines, the process can be site-selective, and different sites can have distinct functional consequences. This step is a key point of regulation because it determines which proteins enter the palmitoylation cycle.
Palmitoyl transfer and thioester bond formation
In simple terms: The enzyme attaches a fatty acid called palmitate to the cysteine sulfur, forming a reversible bond.
During catalysis, the palmitoyl group is transferred to the sulfur atom of the target cysteine, forming a thioester linkage and producing peptidyl-S-palmitoyl-L-cysteine. This covalent attachment increases the hydrophobicity of the protein and promotes association with membrane compartments. The thioester bond is chemically labile, which is the basis for the reversibility of the modification. The reaction is the defining biochemical event of GO:0018230.
Membrane targeting and trafficking consequences
In simple terms: Once palmitate is attached, the protein can stick to membranes and move to new locations.
Following S-palmitoylation, proteins often redistribute to specific membrane domains such as the plasma membrane or Golgi, altering their signaling output. This membrane association can change the accessibility of the protein to substrates, partners or downstream effectors. For example, palmitoylation-dependent regulation of GPX4 suppresses ferroptosis, indicating that the modification affects a critical redox enzyme in a membrane-associated context. Similarly, ROS-dependent S-palmitoylation activates gasdermin D, showing that the modification can be coupled to membrane-related cell death events.
Depalmitoylation and dynamic cycling
In simple terms: Another enzyme can remove the palmitate, so the protein can cycle on and off membranes.
The modification is reversed by thioesterases such as APT1 and APT2, which hydrolyze the thioester bond and release the protein from its palmitate anchor. This creates a dynamic cycle in which proteins repeatedly associate with and dissociate from membranes, allowing rapid responses to cellular signals. The balance between palmitoylation and depalmitoylation determines steady-state localization and function. Disruption of this cycle can alter protein stability and signaling, which is relevant to cancer and other diseases.
Functional outcomes in autophagy and cancer
In simple terms: Palmitoylation can switch on processes like autophagy and cancer-promoting signaling.
S-palmitoylation regulates autophagy through ZDHHC7-mediated modification of ATG16L1, which facilitates LC3 lipidation and autophagosome formation. In cancer, ZDHHC20-mediated S-palmitoylation of FASN promotes hepatocarcinogenesis, and ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. These examples show that the same core biochemical process can drive distinct disease-relevant programs depending on the substrate and enzyme. Collectively, they illustrate why GO:0018230 is a functionally diverse and therapeutically relevant process.
Key Genes Involved in GO:0018230 peptidyl-L-cysteine S-palmitoylation
The following genes and proteins are experimentally implicated in peptidyl-L-cysteine S-palmitoylation, either as writers, erasers, substrates or downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ZDHHC20 | Palmitoyl acyltransferase that modifies FASN and YTHDF3 | Promotes hepatocarcinogenesis and pancreatic cancer progression |
| ZDHHC7 | Palmitoyl acyltransferase that modifies ATG16L1 | Regulates LC3 lipidation and autophagosome formation |
| GPX4 | Substrate whose palmitoylation suppresses ferroptosis | Links palmitoylation to oxidative cell death |
| GSDMD | Substrate activated by ROS-dependent S-palmitoylation | Connects palmitoylation to inflammatory cell death |
| FASN | Substrate palmitoylated by ZDHHC20 | Drives hepatocarcinogenesis |
| YTHDF3 | Substrate palmitoylated by ZDHHC20 | Stabilizes MYC mRNA in pancreatic cancer |
| ATG16L1 | Substrate palmitoylated by ZDHHC7 | Facilitates LC3 lipidation and autophagosome formation |
| APT1 | Thioesterase that removes palmitate | Controls depalmitoylation and cycling |
| APT2 | Thioesterase that removes palmitate | Controls depalmitoylation and cycling |
| ZDHHC family | Enzyme family that writes S-palmitoylation | Central to substrate selection and disease mechanisms |
| MYC | Downstream oncogene stabilized via YTHDF3 palmitoylation | Readout of palmitoylation-dependent cancer signaling |
| LC3 | Downstream effector of ATG16L1 palmitoylation | Marker of autophagosome formation |
| GPX4 pathway | Redox defense linked to ferroptosis | Therapeutic target in ferroptosis-related disease |
| GSDMD pathway | Inflammatory cell death effector | Target in inflammation and pyroptosis research |
| FASN pathway | Lipid synthesis enzyme | Metabolic target in liver cancer |
| YTHDF3-MYC axis | mRNA stability module | Target in pancreatic cancer |
| ATG16L1-LC3 axis | Autophagy machinery module | Target in autophagy-related disease |
How Is peptidyl-L-cysteine S-palmitoylation Regulated?
Peptidyl-L-cysteine S-palmitoylation is regulated at multiple levels, including the expression and localization of ZDHHC-family acyltransferases and thioesterases, the availability of palmitoyl-CoA, and the redox state of the cell. Because the modification is reversible, the balance between writing and erasing enzymes determines the steady-state palmitoylation level of a given substrate. Stimulus-dependent regulation is illustrated by ROS-dependent S-palmitoylation of gasdermin D, which shows that oxidative signals can directly influence the modification. Substrate-specific regulation also occurs through accessory proteins and membrane context, which can alter enzyme-substrate encounters. In cancer, dysregulated expression of enzymes such as ZDHHC20 can shift the palmitoylation landscape and promote oncogenic signaling. Autophagy-related regulation through ZDHHC7 and ATG16L1 further demonstrates that the process is integrated with cellular stress and degradation pathways.
peptidyl-L-cysteine S-palmitoylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZDHHC20 | Hepatocarcinogenesis and pancreatic cancer | Knockout and overexpression in liver and pancreatic cancer cell lines |
| GPX4 | Ferroptosis suppression | Point-mutation and knockout models to test palmitoylation sites |
| GSDMD | Inflammatory cell death | Knock-in and point-mutation models to test ROS-dependent palmitoylation |
| ATG16L1 | Autophagy regulation | Knockout and tagged knock-in models to track LC3 lipidation |
| FASN | Metabolic reprogramming in liver cancer | Overexpression and knockout models in hepatocarcinoma cells |
Cancer
S-palmitoylation is increasingly recognized as a driver of cancer-relevant signaling and metabolism. ZDHHC20-mediated S-palmitoylation of FASN promotes hepatocarcinogenesis, and ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. These findings position palmitoylation enzymes and their substrates as candidate therapeutic targets in oncology.
Ferroptosis and oxidative cell death
Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis, linking GO:0018230 to oxidative cell death pathways. Because ferroptosis is implicated in cancer and other diseases, understanding how palmitoylation controls GPX4 may inform strategies to modulate cell death.
Inflammatory cell death
ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D, connecting the modification to inflammatory cell death. This suggests that palmitoylation may influence the intensity and context of pyroptosis-related responses.
Autophagy-related pathology
ZDHHC7-mediated S-palmitoylation of ATG16L1 facilitates LC3 lipidation and autophagosome formation, tying the process to autophagy regulation. Dysregulated autophagy is relevant to cancer, neurodegeneration and metabolic disease, making this axis a focus of ongoing research.
From peptidyl-L-cysteine S-palmitoylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a palmitoyltransferase affect substrate localization? | CRISPR knockout of the ZDHHC gene |
| Is a specific cysteine required for substrate function? | Point mutation of the cysteine to alanine |
| Can a disease-associated variant alter palmitoylation? | Knock-in of the variant allele |
| Where and when does a substrate become palmitoylated? | Tagged knock-in with a reporter or affinity tag |
| Does increased enzyme dosage drive oncogenic signaling? | Overexpression of the writer enzyme |
| Does palmitoylation control cell death sensitivity? | Knockout or point-mutation models in ferroptosis or pyroptosis assays |
How to Study the peptidyl-L-cysteine S-palmitoylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Click chemistry with palmitate analogs | Presence and level of S-palmitoylation | Confirm substrate modification |
| Mass spectrometry proteomics | Palmitoylated proteins and cysteine sites | Global and site-specific mapping |
| Fluorescence imaging | Membrane localization and trafficking | Test localization changes after enzyme perturbation |
| Ferroptosis assay | Sensitivity to oxidative cell death | Test GPX4 palmitoylation function |
| Pyroptosis assay | Gasdermin D activation | Test ROS-dependent palmitoylation |
| Autophagy flux assay | LC3 lipidation and autophagosome formation | Test ATG16L1 palmitoylation function |
| CRISPR knockout screening | Causal role of writer and eraser genes | Identify regulators of palmitoylation-dependent phenotypes |
| RNA-seq and MYC target analysis | Downstream transcriptional output | Test YTHDF3-MYC axis in cancer cells |
Metabolic labeling and click chemistry
Palmitoylation can be detected using alkyne- or azide-functionalized palmitate analogs followed by click chemistry, which allows visualization and enrichment of modified proteins. This approach is widely used to confirm that a candidate substrate undergoes S-palmitoylation and to compare modification levels across conditions.
Proteomics and site mapping
Mass spectrometry-based proteomics can identify palmitoylated proteins and map specific cysteine sites, providing a global view of the palmitoylation landscape. Site mapping is essential for designing point-mutation experiments that test the function of individual cysteines.
Imaging and membrane localization assays
Fluorescence imaging of tagged proteins can reveal how palmitoylation changes membrane association and subcellular distribution. These assays are often combined with depalmitoylation inhibitors or enzyme knockdown to test reversibility.
Functional assays for disease phenotypes
Ferroptosis, pyroptosis and autophagy assays can be used to test the functional consequences of altered palmitoylation. For example, GPX4 palmitoylation can be linked to ferroptosis sensitivity, and ATG16L1 palmitoylation can be linked to LC3 lipidation and autophagosome formation.
How CRISPR Can Be Used to Study GO:0018230 peptidyl-L-cysteine S-palmitoylation
Knockout
CRISPR knockout of ZDHHC-family acyltransferases or thioesterases can remove the writer or eraser activity and reveal whether a phenotype depends on S-palmitoylation. Knockout of ZDHHC20, for example, can test its role in FASN or YTHDF3 palmitoylation and downstream cancer phenotypes. Knockout of ATG16L1-modifying enzymes can test effects on LC3 lipidation and autophagy.
Point Mutation
Point mutation of the target cysteine to a non-palmitoylatable residue such as alanine is a direct way to test whether a specific S-palmitoylation site is required for function. This approach is especially useful for substrates such as GPX4, gasdermin D and ATG16L1, where site-specific modification may control distinct outcomes.
Knock-in
Knock-in of disease-associated variants or tagged alleles allows researchers to study palmitoylation in a physiological context. Tagged knock-in can enable endogenous tracking of modified proteins, while variant knock-in can test whether a patient-derived mutation alters modification or function.
Overexpression
Overexpression of a writer enzyme or substrate can test gain-of-function effects, such as whether increased ZDHHC20 drives oncogenic signaling through FASN or YTHDF3. Overexpression models are also useful for validating downstream readouts like MYC mRNA stability or lipid synthesis.
How EDITGENE Supports peptidyl-L-cysteine S-palmitoylation Research
Researchers studying peptidyl-L-cysteine S-palmitoylation-related genes often need to determine whether a candidate gene is causally involved in substrate modification, localization or disease phenotypes, and CRISPR-based models provide a direct way to test these hypotheses.
Contact EDITGENE today to design your custom CRISPR model for peptidyl-L-cysteine S-palmitoylation research.
Frequently Asked Questions About peptidyl-L-cysteine S-palmitoylation
What is peptidyl-L-cysteine S-palmitoylation?
It is the covalent attachment of a palmitoyl group to a cysteine sulfur atom in a protein, forming peptidyl-S-palmitoyl-L-cysteine, as defined by GO:0018230.
What genes are involved in peptidyl-L-cysteine S-palmitoylation?
Key genes include ZDHHC-family acyltransferases such as ZDHHC20 and ZDHHC7, thioesterases such as APT1 and APT2, and substrates such as GPX4, GSDMD, FASN, YTHDF3 and ATG16L1.
Why is S-palmitoylation reversible?
The thioester bond between palmitate and cysteine sulfur is labile and can be hydrolyzed by thioesterases, allowing dynamic cycling.
How is S-palmitoylation linked to cancer?
ZDHHC20-mediated S-palmitoylation of FASN promotes hepatocarcinogenesis, and ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression.
What is the role of palmitoylation in ferroptosis?
Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis, linking the modification to oxidative cell death.
How does palmitoylation affect gasdermin D?
ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D, connecting the process to inflammatory cell death.
Does palmitoylation regulate autophagy?
Yes, ZDHHC7-mediated S-palmitoylation of ATG16L1 facilitates LC3 lipidation and autophagosome formation.
What methods are used to study S-palmitoylation?
Common methods include click chemistry with palmitate analogs, mass spectrometry proteomics, fluorescence imaging and functional assays for ferroptosis, pyroptosis and autophagy.
How can CRISPR help study S-palmitoylation?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of writer enzymes, erasers and substrate sites.
Which enzymes remove palmitate from proteins?
Acyl-protein thioesterases such as APT1 and APT2 remove palmitate and reverse the modification.
Conclusion
GO:0018230 peptidyl-L-cysteine S-palmitoylation is a reversible lipid modification that controls protein localization, stability and signaling, with direct links to cancer, ferroptosis, inflammatory cell death and autophagy. The process is written by ZDHHC-family enzymes and erased by thioesterases, making it a dynamic and druggable regulatory node. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal evidence needed to move from correlation to mechanism in this field.
References
- 1. Huang B et al.. 2025. Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis.. Nat Commun 16(1):867 PMID: 39833225
- 2. Mo Y et al.. 2024. ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis.. Mol Cancer 23(1):274 PMID: 39696259
- 3. Du G et al.. 2024. ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D.. Nature 630(8016):437-446 PMID: 38599239
- 4. S Mesquita F et al.. 2024. Mechanisms and functions of protein S-acylation.. Nat Rev Mol Cell Biol 25(6):488-509 PMID: 38355760
- 5. Ko PJ et al.. 2018. Protein palmitoylation and cancer.. EMBO Rep 19(10) PMID: 30232163
- 6. Zhang H et al.. 2024. ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression.. Nat Commun 15(1):4642 PMID: 38821916
- 7. Wei F et al.. 2024. ZDHHC7-mediated S-palmitoylation of ATG16L1 facilitates LC3 lipidation and autophagosome formation.. Autophagy 20(12):2719-2737 PMID: 39087410
- 8. Zhou B et al.. 2023. Protein palmitoylation in cancer: molecular functions and therapeutic potential.. Mol Oncol 17(1):3-26 PMID: 36018061
